Denali Therapeutics Inc (DNLI) Receives Consensus Rating of “Hold” from Analysts

Shares of Denali Therapeutics Inc (NASDAQ:DNLI) have earned a consensus recommendation of “Hold” from the six analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $24.00.

Separately, Zacks Investment Research downgraded Denali Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 14th.

Shares of DNLI stock opened at $19.55 on Wednesday. The company has a market cap of $2.06 billion and a PE ratio of -3.32. Denali Therapeutics has a 1-year low of $12.32 and a 1-year high of $25.79.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, August 9th. The company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.39). The company had revenue of $1.65 million during the quarter, compared to analysts’ expectations of $3.00 million. Research analysts anticipate that Denali Therapeutics will post -1.2 earnings per share for the current year.

In related news, insider Ryan J. Watts sold 18,334 shares of the stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $18.05, for a total value of $330,928.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ryan J. Watts sold 18,333 shares of the stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $19.06, for a total value of $349,426.98. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,167 shares of company stock valued at $1,060,456. 21.30% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Baillie Gifford & Co. raised its stake in Denali Therapeutics by 2.9% in the 2nd quarter. Baillie Gifford & Co. now owns 5,344,633 shares of the company’s stock valued at $81,506,000 after purchasing an additional 151,787 shares during the last quarter. BlackRock Inc. raised its stake in Denali Therapeutics by 6.4% in the 2nd quarter. BlackRock Inc. now owns 1,121,358 shares of the company’s stock valued at $17,101,000 after purchasing an additional 67,420 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in Denali Therapeutics in the 1st quarter valued at $5,604,000. Jasper Ridge Partners L.P. purchased a new stake in Denali Therapeutics in the 2nd quarter valued at $4,289,000. Finally, Allianz Asset Management GmbH grew its holdings in Denali Therapeutics by 18.4% in the 1st quarter. Allianz Asset Management GmbH now owns 236,290 shares of the company’s stock valued at $4,653,000 after buying an additional 36,745 shares in the last quarter. 65.05% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Read More: What is a stock split?

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply